SHYNDEC: Famotidine injection has passed the consistency evaluation of quality and efficacy for generic drugs
SHYNDEC announced that its wholly-owned subsidiary China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for Famotidine injection to pass the consistency evaluation of quality and efficacy for generic drugs. Famotidine is a histamine H2 receptor antagonist used to treat peptic ulcers and related bleeding
According to the announcement from China National Pharmaceutical Group Modern (600420.SH), the company's wholly-owned subsidiary China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Rongsheng) has received the "Approval Notice for Supplementary Drug Application" issued by the National Medical Products Administration, approving Famotidine injection to pass the consistency evaluation of quality and efficacy for generic drugs.
Famotidine is a histamine H2 receptor antagonist used for upper gastrointestinal bleeding caused by peptic ulcers, as well as for gastric and duodenal mucosal erosion bleeding caused by various reasons other than tumors and esophageal and gastric varices
